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The therapeutic application of nanomaterials requires that they are biocompatible and can 
reach the desired target. The innate immune system is likely to be the first defence 
machinery that would recognise the nanomaterials as ‘non-self’. A number of studies have 
addressed the issue of how carbon nanotubes (CNTs) interact with phagocytic cells and their 
surface receptors that can impact on their intracellular processing and subsequent immune 
response. In addition, soluble innate immune factors also get involved in the recognition 
and clearance of CNTs. The interaction of CNTs with the complement system, the most 
potent and versatile innate immune mechanism, has shed interesting light on how 
complement activation on the surface of CNTs can modulate their phagocytosis and effector 
cytokine response. The charge or altered molecular pattern on the surface of CNTs due to 
functionalization and derivatisation can also dictate the level of complement activation and 
subsequent inflammatory response. It is becoming evident that complement deposition 
may facilitate phagocytic uptake of CNTs through receptor routes that leads to dampening 
of pro-inflammatory response by complement-receptor bearing macrophages and B cells. 
Thus, recombinant complement regulators decorated on the CNT surface can influence the 





































































CNT characteristics and applications 
Since lijima described their synthesis in 19911carbon nanotube (CNT)-based nanotechnology 
has rapidly emerged as a platform for a variety of uses, including many biomedical 
applications2. CNTs can be described as cylindrical tubes, composed of rolled graphene, with 
the carbon atoms hybridized in hexagonal sp2 arrangement and consist of honeycomb 
lattices and are seamless structure. Each atom is joined to three other neighbour atoms just 
like in graphene. The type of CNTs depends on the orientation of the rolling of graphene 
sheet.  Based on the rolling orientation of graphene sheet, CNTs are classified as arm chair, 
zigzag and chiral nanotubes3. CNTs can be described as cylindrical tubes, composed of rolled 
graphene, with the carbon atoms hybridized in hexagonal sp2 arrangement. Depending on 
the number of concentric carbon tubes, they can be divided into single-walled (SWNT), 
double-walled (DWNT) and multi-walled (MWNT) carbon nanotubes (Figure 1a-b). A 
principal characteristic is their high aspect ratio, resulting from their small diameter (1-3 nm 
for SWNT up to 2-100 nm for MWNTs) and extended length (up to 500 µm), which arise 
from their method of synthesis 4. CNTs are grown on a substrate, either with or without 
(metallic) catalyst particles; the preparation methods include arc discharge, laser ablation 
and chemical vapour deposition (Figure 1c)5. 
Biomedical applications of CNTs include drug delivery6-11, immunoassays12 and scaffold13, 14. 
In combination with magnetic filling or particles, CNTs can be used as an MRI contrast 
agent15-20, and in hyperthermia treatment21, 22. As their most promising application, CNTs as 
drug delivery platforms have been reviewed extensively elsewhere6, 23-25. The large surface 
area of CNTs offers a substantially higher drug loading capacity, compared to other 
nanoparticles while the dimensions of CNTs allow for entry in the smallest capillaries26. 
Compatible with the requirement for targeted drug delivery, CNTs are able to cross the cell 
and nuclear membrane27-30. Drugs can be either entrapped inside the CNTs31, or absorbed or 
attached on the surface 9, 10, 32. Using these methods, CNTs have been shown to be versatile 
carriers for a range of drugs6, 11, 23, 25, 32-37, genes38, proteins39 and peptides28. The drugs can, in 
principle, be delivered to specific targets (e.g. tumours) by attaching target-specific 
molecules (e.g. antibodies) 40, 41. 

























































In order to be used for a variety of applications, CNTs have to be individually dispersed in 
physiological buffers. Owing to their hydrophobicity, strong π-π interactions and length, 
CNTs are prone to rope and cluster formation; therefore, functionalizing or coating CNTs is 
essential42. Non-covalent modifications of the CNT surfaces include pre-coating with 
proteins43, surfactants44, synthetic polymers45and nucleic acids46. Covalent functionalization 
involves introducing new functional groups on the external walls, usually beginning with the 
oxidation of the walls creating defects and carboxyl groups47. The biocompatibility of CNTs 
can only be achieved by the covalent or non-covalent functionalization of their surface34, 48-51.  
In all biomedical applications, permanent or transient contact between CNTs and blood, 
cells or tissues is unavoidable, and, hence, an encounter with the immune system. These 
interactions may lead to severe inflammatory responses and tissue damage52, which is likely 
to interfere with the tissue targeting or intended destination of the CNTs. It is, therefore, 
essential to study and understand the interactions between CNTs and all components of the 
immune system. In this review, we focus on the interactions of CNTs with the innate 
immune system, the body's first line of defence, which is likely to have the largest influence 
on host-CNT interaction. 
The innate immune system 
The immune system is responsible for protection against micro-organisms (bacteria, fungi, 
viruses and parasites). In addition, altered or damaged cells and tissues are also cleared via 
the cellular and molecular immune components. Recognition of these altered self or non-
self materials (e.g. synthetic nanoparticles) is mediated by specific proteins, which bind to 
their targets and trigger downstream effector functions with the goal of eliminating the 
imminent danger to homeostasis. The human immune system consists of a complex 
conglomeration of interacting proteins and cells. In order to enhance short and long term 
efficiency of the clearance mechanisms, the immune system operates via two wings: innate 
immunity (rapid and broad in specificity) and adaptive immunity (slow and highly specific). 
The innate immune system involves proteins, always present in the blood, body fluids and 
tissues, while in adaptive immunity new recognition proteins (e.g. antibodies) are generated 
specifically towards a newly presented threat. 

























































A major part of the innate immune system response involves opsonisation of the target 
(e.g., a pathogen) by proteins of the complement system, migration and activation of 
phagocytic cells, mainly macrophages and immature dendritic cells (DCs). The complement 
system consists of more than 40 soluble and cell surface proteins, working together via 
three activation pathways in order to recognise and opsonise foreign and altered-self 
components (Figure 2) 53. The recognition proteins of the complement system work through 
“multiple low-affinity binding”. A single binding between the recognition protein with its 
target, which can be a molecular motif such as a charge cluster, single neutral sugar, vicinal 
hydroxyl groups or a single acetyl group, is not strong enough to hold the target and the 
complement recognition protein together. Therefore, the recognition proteins have a 
multimeric structure with multiple contact/binding sites. The complement cascade is only 
activated when multiple bonds are formed allowing for a strong interaction. 
The complement classical pathway is initiated by C1q (Figure 3), a charge pattern 
recognition protein (460 kDa), consisting of 18 homologous polypeptide chains (6A, 6B and 
6C chains) each consisting of a short N-terminal region, followed by a collagen like region 
with repeating Gly-X-Yaa triplets, and a heterotrimeric globular head (gC1q) domain 
composed of C-terminal region of A, B and C chains (ghA, ghB and ghC, respectively) (Figure 
3). The gC1q domain binds to charge clusters or hydrophobic patches on the targets which 
can altered or non-self ligands 54. In the lectin pathway, the recognition proteins include 
mannan- binding lectin (MBL) that mainly binds to vicinal diols on sugars such as mannose, 
fucose or glucosamine; collectin 11 (CL-11) that binds to more complex glycan motifs; or one 
of the three ficolins (L-,H- and M-ficolin) that bind to acetyl groups and possibly other motifs 
55. After C1q is bound to its targets, proteases C1r and C1s are activated (or for MBL, CL-11 
and ficolins, MBL-associated serine proteases, MASP-1, 2 and 3, are activated). This then 
activates complement proteins C4 and C2 forming a C3 convertase (C4b2a), which cleaves 
C3 to form C3b that then binds to the target surface. C3b and its breakdown products, iC3b 
and C3dg, interact with C3 receptors on phagocytic and other cells.  C3b is also a binding site 
for C5, which is activated by the same protease which cleaves C3, and then forms a complex 
with C6, C7, C8 and C9 (C5-9), called membrane attack complex (MAC), which disrupts the 
lipid bilayer of cells (Figure 2) 55. 

























































The activation of the complement alternative pathway involves a constant slow hydrolysis of 
C3 in solution, which forms C3(H2O), and alters the shape of the protein. This 
conformational change allows the formation of a complex between factor B and C3(H2O), 
which allows factor D to cleave the bound factor B into Ba, which is removed and Bb, which 
remains bound. C3(H2O)Bb  is a protease which cleaves more C3 to form C3b, which can 
bind to target surfaces, and form a complex with factor B, which is converted to C3bBb, by 
factor D, as above. This leads to coating of the target particle with C3bBb, which is a 
homologue of the classical pathway C3 convertase, C4b2a. C3bBb, the alternative pathway 
C3 convertase, can be further stabilized by properdin (factor P) to C3bBbP. This complex is 
an enzyme able to generate more C3b to bind to targets. This is an amplification mechanism 
in order to increase turnover of C3 and coating of targets with C3b.  To avoid consuming all 
available C3, the amplification mechanism needs to be balanced by down regulators: Factor 
H binds to C3b inhibiting C3 convertase formation, and together with factor I it cleaves C3b 
to iC3b, which is unable to form C3bBb 55-57. 
After the complement proteins have tagged a particle (opsonisation), there follows 
interaction with cell bound receptors (e.g. red blood cells through CR1/CR35, a receptor for 
C3b) and phagocytosis (via CR3 and CR4, which are receptors for iC3b). These complement-
receptor interactions also promote uptake of complement-activating targets by DCs. Once 
immature DCs ingest an antigen, they undergo a directed activation and maturation towards 
becoming a potent antigen presenting cell (APC), after which they migrate towards lymph 
nodes. This makes DCs the main link between the innate and adaptive immune system, as 
they provide signals for T lymphocytes with the specific receptors for the presented 
epitopes to become activated58.  
Interactions of CNTs with human plasma proteins 
CNTs not only interact with components of the immune system but also show highly specific 
interactions with other soluble plasma proteins59. The bound proteins form a corona, which 
plays an important role in determining the effective size, surface charge, physicochemical 
properties and aggregation state of the nanoparticles60. In addition, it changes the 
recognition patterns, possibly presenting novel peptide or glycan motifs to the immune 

























































system, and can therefore alter the nature of interaction with the complement system, cells 
and ultimately immune response and bio-distribution 61-64. 
The composition of the protein corona changes with time, depending on the binding 
affinities and stoichiometry of the nanocarrier and proteins 65. Affinities can be affected by 
surface properties such as available functional groups, but also the surface area and 
curvature. In general, a nanocarrier will be first covered by the most abundant plasma 
proteins (e.g. albumin and fibrinogen). These proteins are then replaced by proteins with 
higher affinity towards the particle surface, a process called the “Vroman effect” 66-68. The 
initial coating on the CNT can influence the binding of proteins, as some proteins have 
affinities towards charge, hydrophilicity, nucleic acids or carboxyl groups 66. 
Oxidation of CNTs offers a more negatively charged surface, which binds more protein 69, 70. 
Shannahan et al. have performed an extensive proteomics analysis to identify the proteins 
in the corona of SWNTs (1 nm) and MWNTs (20-30 nm) unmodified, PVP 
(Polyvinylpyrrolidone) coated, or oxidised70. All CNT coronas contained 14 common proteins: 
serum albumin, titin, apolipoprotein-A-I, apolipoprotein A-II, α1-anti-proteinase, α2-HS-
glycoprotein, α-S1-casein and keratin. A much larger variety of proteins was found to bind 
only onto specific types of CNTs.  A similar binding profile was found by Salvador-Morales et 
al., but it was reported that more albumin bound to chemically modified MWNTs, 
suggesting that the plasma could enter the larger diameter MWNTs by capillary forces; 
these entrapped proteins are likely to be difficult to wash out 71, 72. Cai et al. showed that 
larger diameter CNTs were also able to bind a wide range of proteins on their surfaces, 
although increasing the diameter of CNTs above 20 nm did not have any additional effect 73.  
Complement absorption and activation 
Certain components of the corona, opsonins, which include IgG, complement proteins and 
fibrinogen, may enhance uptake of the nanoparticles by macrophages and other cells of the 
reticulo-endothelial system 48, 64. The importance of complement activation by nanoparticles 
used in drug targeting was highlighted by a study on liposome-encapsulated-doxorubicin. 
After hypersensitivity reaction was reported in clinical application of these particles, it was 
found that these side effects were caused due to complement activation74.  

























































Previous studies have shown that non-functionalized CNTs, when placed in contact with 
human serum, activate complement via the classical and, to a lesser extent, via the 
alternative pathway71, 75. However, the mode of binding of the recognition proteins to the 
CNTs has not fully been characterised and questions remain whether complement proteins 
bind directly to the CNTs or bind via other deposited (serum) proteins that can act as 
adaptors. Complement proteins C1q and MBL, as well as C-reactive protein, an acute phase 
protein which itself mediates binding of C1q (an “adaptor” for C1q), are known to recognise 
repetitive structures or charge patterns, which are not found on pristine CNTs but 
commonly found on the surface of functionalized CNTs76. Ling et al. presented evidence that 
C1q “crystallizes” on pristine and functionalized CNTs, but is not bound in a way that allows 
it to activate the next step of the complement cascade77. Other serum proteins would thus 
have to form a stable layer on the CNTs for indirect C1 binding and subsequent complement 
activation. Others71, 75, 78, 79, however, observed direct high affinity binding of C1q to CNTs by 
hydrophobic interactions, and concluded that direct binding of C1 would allow complement 
activation. Binding of C1q onto CNTs is not ionic or calcium-ion-dependent and is of high 
affinity since denaturation of C1q is required to remove the C1q from the CNTs80.  
Recombinant forms of individual globular head regions of C1q A, B and C chains can be 
bound to pristine, oxidised and carboxymethyl (CMC) cellulose coated MWNTs78, 79, 
confirming that the binding of C1q to CNTs takes place via the gC1q domain, which is the 
principal ligand-recognition domain of C1q81. Binding of C1 is followed by activation of C4 
and C2, but activation may not go beyond that due to the lack of suitable covalent binding 
(OH, NH2 or SH) sites for C4b or C3b82. However, it has been shown that C3 and C5 turnover 
did occur with pristine and various proteins coated CNTs 79. Therefore, it is likely that C3b 
binds and the MAC is subsequently formed. These interactions of C3b and C4b are most 
likely via direct hydrophobic interactions with the surface of the CNTs80. Similarly, another 
key component and up-regulator of the complement alternative pathway, properdin, which 
has previously been shown to bind to apoptotic T cells83 and DNA exposed on apoptotic and 
necrotic cells84, has recently shown pattern recognition properties and binds to both CMC-
CNTs and Ox-CNTs and enhances their uptake by macrophages in a complement-
independent manner.  Furthermore, CNTs bound properdin still retains its C3 and C5 
convertase stabilisation properties and activates the alternative pathway. However, 

























































recombinant thrombospondin repeats (TSR) 4 and 5, the modules of human properdin that 
can bind C3b, acts as a potent inhibitor of the alternative pathway and also inhibit the rapid 
macrophage mediated clearance, raising the possibility of therapeutic use in a range of 
diseases, including tumour85. CNTs, opsonised with human properdin or TSR4+5, triggered a 
robust pro-inflammatory response by macrophages, suggesting that local synthesis of 
complement proteins can alter the immune clearance of nanoparticles considerably, even 
when there is no complement activation involved. 
Differential innate immune recognition of CNTs based on functionalisation 
Several studies have shown that functionalization, and therefore, alteration in the surface 
properties of the CNTs, can change the extent of complement activation49, 52, 69, 78-80, 86, 87. Pre-
coating CNTs will increase the dispersion state, making more surface area available for 
complement proteins to recognise and deposit themselves. RNA and BSA, used as dispersing 
agents, do not uniformly coat the CNT surface, therefore, binding sides on the CNT surface 
are made more available and complement activation might increase compared to clustered 
pristine CNTs. RNA itself can interact with C1q providing an additional binding site for 
complement80. Poly-ε-caprolactam (Nylon-6) and CMC-cellulose have been shown to reduce 
the level of complement activation via the classical pathway most efficiently, but fail to 
eliminate opsonisation52, 79.  
Until a decade ago, PEGylation (Poly ethylene glycol coating) was considered to provide a 
shielding surface on nanoparticles, but in 2002, it was shown that PEGylated polystyrene 
microspheres could activate complement, depending on the configuration of the PEG on the 
surface88. The effects of PEGylation on SWNTs as well as MWNTs have been extensively 
studied by the Moghimi group. They showed that although PEG can reduce complement 
activation via both classical and alternative pathway, levels of both C4d (cleavage product of 
C4) and MAC significantly increased. They concluded that complement activation was likely 
to occur through the lectin pathway. For MWNTs, complement activation was independent 
of the molecular mass of PEG chains and the effect was not caused by uncoated regions of 
the CNTs. The surface domains of the PEG derivatives may thus act as templates for the 
lectin pathway activating molecules (L-ficolin and MASP-2) 86, 89, 90. 

























































Complement activation can be influenced by coating specific humoral factors onto the outer 
walls of CNTs. For instance binding of factor H, a down-regulator of the alternative pathway, 
lowers the activation of the alternative pathway52. In contrast to full length C1q, the 
recombinant globular heads of C1q were shown to reduce complement activation 79. This 
phenomenon is likely to be caused by globular heads competing out the binding of whole 
C1q to CNTs, thereby diminishing complement activation. A similar technique to avoid 
recognition by the complement system is used by pathogenic bacteria, which have specific 
binding motifs on their surface to bind factor H, thus inhibiting alternative pathway 
activation 91.  
Innate immune receptors, phagocytosis and immune response 
The cells of the innate immune system, including macrophages and DCs, have pattern 
recognition receptors (PRRs) that recognise and bind pathogens via pathogen-associated 
molecular patterns (PAMPs). These include toll-like receptors (TLRs), scavenger receptors, 
complement receptors, integrins, and lectin-like receptors, which are potentially capable of 
recognising nanoparticles. Once a particle is bound to receptors, the particle will be 
attached to the cell and taken on its path, but can also be phagocytosed and ultimately, if 
possible, digested internally and cleared from the system.  
The most important complement-derived opsonin is C3b and its breakdown product iC3b. 
Multiple copies of C3b bind onto the surface of the nanocarrier. C3b interacts with 
complement receptor 1 (CR1 or CD35) which is abundant on red blood cells. Once C3b has 
bound, it is gradually broken down into iC3b, which has lower affinity towards CR1, but high 
affinity towards CR3 and CR4, which are commonly found on phagocytic cells. Therefore, 
the nanoparticles will be transferred from red blood cells towards phagocytic cells, 
especially during the passage of the red blood cells through the liver where macrophages 
are present in high numbers. The iC3b will be further broken down into C3d, which can 
interact with CR2 (CD21) on the surface of B-lymphocytes, and therefore, interact with the 
adaptive immune system.  
Opsonised CNTs absorb or bind onto the surface of red blood cells (Pondman et al., 
unpublished), indicating that C3b is bound in a conformation that allows interaction with 
CR1. PEGylation, which down-regulates complement activation, was shown to reduce 

























































uptake of CNTs by monocytes, spleen and liver phagocytes that correlated with increasing 
molecular weight and PEG coating density92. Uptake of CNTs by macrophages (U937 cell 
line), blood monocytes and B cells (Raji cell line) is more efficient in the presence of serum; 
while complement inactivated (heat inactivated) serum does not enhance the phagocytosis 
of CNTs, indicating an important additive effect of complement78, 79. Most interestingly, 
Jurkat T cells, which are known to express complement receptors feebly on their surface, 
were able to take up CNTs poorly and serum treatment did not increase uptake78. 
Complement adsorption on the surface of MWNTs was shown to reduce the expression of 
pro-inflammatory cytokines (TNF-α, IL-6 and IL-1β) and increase expression of anti-
inflammatory cytokines (IL-10 and TGF-β) in monocytes and macrophages 79. This indicates 
that complement might signal the cells to silently remove the CNTs by phagocytosis, but do 
not give out stress signals to their microenvironment. Even when only the initial 
complement proteins C1q and MBL are bound on the surface of the CNT, receptor 
interactions are possible with calreticulin, a receptor molecule for C1q and MBL, working 
together with CD91 acting as a C1q receptor93. These bindings are less efficient as the 
density of deposited C1q and MBL is far lower than C3b and for adhesion, hundreds of 
receptor-ligand pairs are needed. As was shown recently, pre-coating the CNTs with the 
recombinant globular head modules of human C1q and its full length counterpart87can 
increase the phagocytosis by macrophages. Similar properties has been shown with 
properdin coated CNTs85 while factor H87 and small fragment of properdin molecule 
(TSR4+5)85 proved to be an inhibitor of phagocytosis. Recently, Meng et al. showed that 
after phagocytosis of ox-MWNTs, macrophages produced macrophage inflammatory 
proteins (MIP-1α and MIP-2) to recruit other macrophages to the site. They also confirmed 
that low levels of pro-inflammatory cytokines were produced94. 
Non-complement dependent uptake of CNTs 
The method of entry of CNTs into cells is a highly debated subject in the literature, 
complement dependent phagocytosis being one of the several mechanisms. Covalent and 
non-covalent modification of CNT walls can alter its interaction with immune cells. In the 
case of the former, that phenomenon can be caused by the chemical nature of the coating. 
For example, macrophages are known to interact more strongly with positively charged 
particles due to the presence of negatively charged sialic acid on their surface 95. However, 

























































altered uptake and interactions can also be a direct effect of the higher dispersibility and, 
therefore, biocompatibility of the functionalized CNTs. In general, hydrophilic or acidic 
polymer coated MWNTs are more efficiently internalized by macrophages than hydrophobic 
polymer coated MWNTs96. Direct penetration or “needling” through the plasma membrane 
is another described phenomenon97, 98. Others state that absorption of albumin or other 
serum proteins is essential to trigger scavenger receptor-mediated uptake99. Kam et al. 
found that very short SWNTS (e.g., 50-200 nm) enter cells (e.g., HeLa and H60 cell lines) 
through clathrin-dependent endocytosis100. However, Pantarotto et al showed that slightly 
longer SWNTs (300-1000 nm) behave like cell penetrating peptides while entering human 
(3T6) and murine (3T3) fibroblasts28.  
After uptake by the cells, the chemically modified CNTs can be found in the cytoplasm, 
endosomes,11, 28, 98, 101, 102, and in some cases, inside the nucleus28, 97, 102.These variations can 
be due to different functionalization28, 97. Exocytosis has not been reported often and the 
time course for the process varies between simultaneous with endocytosis103 and until after 
5 h of incubation78, 79, 101.  
Cytokine, inflammation and immune responses 
In their bio-persistence as well as high aspect ratio, CNTs show similarities to asbestos, and 
therefore, an incomplete uptake and frustrated phagocytosis with the related inflammation 
and granuloma formation is a risk that has to be analysed 98, 104, 105.  Frustrated phagocytosis 
was analysed by Brown et al. with a variety of elongated CNTs106. In their study, only 
individually dispersed long straight CNTs led to frustrated phagocytosis using PBMCs 
(peripheral blood mononuclear cells) and the THP-1 cells, (a monocyte-derived cell line), 
which correlated with superoxide anion and TNF-α release. The presence of CNTs interfered 
with the function of the macrophages as was shown by an inhibition of the ability of THP-1 
cells to phagocytose E. coli. Clustered CNTs and nanofibers did not induce apoptotic or 
necrotic effects106. 
Exposure to long MWNTs resulted in a significant and dose-dependent release of IL-1β, TNF-
α, IL-6 and IL-8 from THP-1, but not from mesothelial cells (Met5a) 104. More interestingly, 
when cell medium from the THP-1 cells treated with long CNTs was added to Met5a cells, 
they too showed an increased cytokine production, indicating the essential role of 

























































macrophages in the immune response towards CNTs. Liu et al. showed that immune 
response with pluronic F127 coated MWNTs in RAW (a murine macrophage cell line) and 
MCF-7 (a breast cancer cell line) cells was length-dependent 105. RAW cells showed higher 
internalisation, resulting in higher toxicity due to CNTs than MCF-7. Long MWNTs (3-8 µm) 
were more toxic than short (<1.5 µm), but short MWNTs gave more TNF-α release than long 
MWNTs, which could lead to a stronger inflammatory response. However, complement 
deposited CNTs dampened the pro-inflammatory cytokines such as IL-1β and TNF-α despite 
higher internalization of these CNTs by human macrophage cell lines79.  
Besides cytokine response, indications of inflammasome formation by CNTs have been 
reported 98, 107, 108. Many carbon nanomaterials (carbon black, short, long and tangled CNTs, 
long needle-like MWNTs, and asbestos) induced IL-1β secretion (indicator of inflammasome 
formation), but only long needle-like CNTs induced IL-1α secretion in LPS-primed 
macrophages98. DWNTs can synergize with TLR4 antagonists; when K+ efflux is hindered, IL-
1β secretion could be eliminated, indicating that phagocytosis was required for 
inflammasome activation. After phagocytosis, NF-kβ (nuclear factor kappa-light-chain-
enhancer of activated B cells) and NLRP3 (nucleotide-binding oligomerization domain 
(NOD)-like receptors family, pyrin domain containing 3) inflammasome are activated 107, 108 
Various CNTs can modulate DC maturation109. Short, purified SWNTs by an oxidation method 
and with free-endotoxin content induced no maturation of DC cultures and did not lead to 
the secretion of IL-6, TNF-α, or IL-1β following their uptake. In comparison, incubation of 
DCs with LPS and CNTs induced IL-1β secretion, which was dose and NLRP3-dependent, 
indicating that LPS contamination causes this effect110. Dumortier et al. showed that PEG1500-
SWNTs are taken up by B- and T-cells without affecting viability of the cells or causing 
damage, inhibiting or stimulating their function 50. Although they found no IL-2 and IFN-α 
secretion (reflecting T cell activation), PEGylated SWNTs did induce IL-6 and TNF-α secretion 
in peritoneal macrophages in vitro, which the authors attributed to the formation of CNT 
aggregates. 
Lung innate immunity and CNTs  
Most likely triggered by their asbestos like appearance111, pulmonary toxicity of CNTs is one 
of the most discussed aspects in the toxicology field. Disagreement started from the very 

























































first studies published by Lam112 and Warheit113 who independently concluded that CNTs 
were highly toxic and non-toxic to the lungs, respectively. First, they both showed that CNTs 
induced granulomas, but only Lam showed subsequent fibrogenesis. This effect can be 
explained by the fact that granuloma formation is mediated by the accumulation of alveolar 
macrophages at sites of CNT deposition, which become activated by the phagocytosis of the 
nanoparticles. The activated macrophages produce growth factors that stimulate the 
proliferation of fibroblasts, the collagen producing cells driving the fibrogenesis114. Whereas 
Lam found a dose- and time-dependent interstitial inflammation, Warheit did not see any 
inflammation and fibrosis; in addition, the granuloma formation was not dose-dependent. 
Warheit concluded that the toxicity of the CNTs was caused by aggregation of the CNTs due 
to the administration method (instillation), which also caused airway blocking. Shvedova et 
al. confirmed the results of Lam et al. in mice and also showed dose-dependent functional 
respiratory deficiencies 115. Subsequently, Mangum et al. found no inflammation in SWNT 
exposed (oropharyngeal aspiration) rats, although they did find a few focal interstitial 
fibrotic lesions at locations with clusters of macrophages containing micron sized aggregates 
of SWNTs in the alveolar region. In addition, they reported, in bronchoalveolar lavage fluid 
(BALF), macrophages linked together with bridges of parallel bundles of SWNTs. They stated 
that this bridge formation is not similar to frustrated or incomplete phagocytosis seen in 
asbestos and other long fibres114. The origin in the variations of effects reported possibly 
owes it to a wide variation in the nanoparticles (single, double or multi-walled) with variable 
diameter and length, coating, aggregation states, contamination with other materials, and 
administration method and route116. By comparing well-dispersed SWNTs with aggregated 
SWNTs, Shvedova et al. found that poorly dispersed SWNTs formed clumps of 5 to 20 µm in 
the lungs, which triggered granuloma formation, whereas highly dispersed SWNTs that did 
not form any clumps and were found free in the tissue, gave rise to interstitial fibrosis but 
no granulomatous lesions117-119. This was confirmed by a study where well dispersed MWNTs 
were found in every cell and cell layer of the lung parenchyma, with signs of interstitial 
fibrosis of the alveolar wall but with very limited granuloma formation120.  
The lung innate immune defence is governed mainly by surfactant proteins A and D (SP-A 
and SP-D), together with lung leukocytes and the epithelial cells lining the alveolar surface. 
Like MBL, SP-A and SP-D are members of the collectin (collagenous lectins) family. SP-A and 

























































SP-D have a multimeric structure similar to C1q and MBL. Among other roles, SP-A and SP-D 
bind to invading particles (commonly via  vicinal diols) in a Ca2+-dependent manner and 
promote their binding to receptors on alveolar macrophages 121. The concentrations of SP-A 
and SP-D are very low, and therefore, binding of these pulmonary surfactant proteins to 
CNTs can cause significant depletion of the proteins and damage to the pulmonary innate 
immune defence mechanisms 72.  
Selective Ca2+-dependent binding of BALF SP-A and SP-D to the oxygen containing functional 
groups on the surface of CNTs was confirmed in a study by Salvador-Morales by using acid 
treated (oxidized) MWNTs, which could be coated entirely with SP-A122. Oxidized DWNTs 
bound SP-A and SP-D more efficiently than non-oxidized DWNTs and purified DWNTs. 
Similar results were found for MWNTs and ox-MWNTs by Marchetti et al.123. 
SP-A-coated MWNTs were able to enter the cytoplasm and the nucleus of alveolar 
macrophages. Interestingly, the high nitric oxide secretion evoked by pristine MWNTs and 
BSA-coated MWNTs was not observed by SP-A-coated MWNTs, indicating a possible method 
to avoid an inflammatory response towards CNTs 122. Allowing SWNTs to obtain a lung 
surfactant corona, consisting of SP-A, B and D, enhanced the in vitro uptake of SWNT by 
RAW cells (murine macrophages) 124. Gasser et al. showed that pre-coating MWNTs (pristine, 
oxidised and aminated) with pulmonary surfactant proteins induces clusters of coated 
MWNTs intracellulary in monocyte-derived macrophages, while more stable suspensions 
are obtained with coated MWNTs 125. It has been argued that both SP-A and 
phosphatidylserine might represent an “eat me” signal towards macrophages. A similar 
effect was seen by coating CNTs with SP-D 126. Coating the MWNTs with SP-D slightly 
increased apoptosis while necrosis slightly decreased 125. Interestingly, a decrease in TNF-α 
release was found, which might be attributed to the phosphatidylserine present in the 
surfactant. 
Coating of CMC-MWNTs and Ox-MWNTs with recombinant SP-D (rhSP-D) increased the 
phagocytosis by macrophages 2-fold, at the same time enhanced the cytokine storm 
provoked by MWNTs (reduction of IL-12, TGF-β, IL-1β, IL-6 and TNF-α production)126. 
Interestingly, SP-D coated CNTs enhanced the complement activation and SP-D coated and 

























































complements deposited CNTs showed the dramatic reduction of pro-inflammatory 
cytokines production compared to SP-D coated CNTs126.  
Conclusions 
A number of studies have addressed how CNTs interact with the innate immune system 
including complement proteins, macrophages, dendritic cells, cell surface pattern 
recognition receptors and soluble factors. The results obtained thus far paint a varied and 
heterogeneous picture: primarily owing to the diverse range of types of CNTs and 
experimental in vitro and in vivo model systems used for investigation. However, it is 
evident that the previously suggested pro-inflammatory response to CNTs needs to be 
viewed in the context of complement. The recognition subcomponents of the three 
pathways of the complement system are fully capable of binding via patterns presented as 
an array over the surface of pristine or chemically-modified CNTs. This recognition can lead 
to complement deposition, thus enhancing phagocytosis by the immune cells bearing 
complement receptors such as macrophages and B cells. Complement deposition on the 
CNTs appears to skew the pro-inflammatory response towards an anti-inflammatory one, 
suggesting beneficial effects of complement. It is unclear how complement deposition 
enhances anti-inflammatory immune response although a link between heightened IL-10 
levels and suppressed TNF-α and IL-1β is evident in recent studies. It is worth examining 
how altered pattern can affect CNT engagement with TLRs with or without complement 
deposition. Clearly, the ability of CNTs to induce pro-inflammatory and anti-inflammatory 
immune response requires a comprehensive in vivo assessment to prove their feasibility 
usage as therapeutic vehicles in the long term. Thus, their potency to deposit complement 
on the surface is going to acquire importance. There are a number of conflicting data in the 
literature that have arisen out of variability of the CNTs introduced by surface coating, 
shapes, sizes, dispersion, and surface charge. With advancement in the production of CNTs, 
such issues can be resolved. It is also important to note that the ability of CNTs to activate 
complement has been reported consistently by a range of research groups. Thus, any clinical 
trials involving CNTs, or for that matter, any nanoparticle, needs to include quality control 
involving innate immune aspects. 
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Figure 1 (A) TEM micrograph of MWNTs, clearly showing the high number of concentric 
carbon sidewalls and a 5 nm inner tube diameter. The outer walls off the MWNT are 
undamaged. (B). SEM micrograph of “as grown” MWNTs on a surface, also known as 
nanotube forest grown by chemical vapour deposition. These MWNTs are approximately 
300 µm in length and 50 nm in diameter. On the top, remainder of the catalyst layer can be 
seen. (C) Sketch of the structure of carbon nanotubes showing different number of 
concentric carbon sidewalls 
Figure 2. The three complement pathways: Classical, lectin and alternative pathways, have 
different recognition strategies. The classical pathway is activated by recognition and 
binding of antigen-antibody complexes binding via C1q, which in turns activates C1r and 
C1s. C1a, cleaves inactive C4 and C2 in sequence to form active C3 convertase, C4b2a. The 
lectin pathway is initiated by binding of mannose or carbohydrates moieties with MBL or 
ficolins activating membrane associated serine proteases (MASPs), which cleave C4 and C2 
to form common C3 convertase (C4b2a). The alternative pathway is spontaneously activated 
by spontaneous lysis of C3 to C3b. Factor D cleaves factor B and forms C3 convertase 
(C3bBb) which in turns cleaves C3 leading to amplification of C3b formation and C5 
convertase (C3bBbC3b). C3 convertase is stabilized by properdin while Factor H acts as an 
antagonist. Factor H inactivates C3b to form inactive iC3B. C5 convertase cleaves C5 forming 
C5B which combines with C6, C7, C8 and C9 to form membrane attack complex (MAC) 
leading to cell lysis. C3b acts as an opsonin and facilitates rapid macrophage mediated 
clearance of foreign particles. C4a, C3a and C5a acts as anaphylatoxins and enhance the 
inflammation 
Figure 3. Overall structure of C1q and surfactant protein SP-D. (a) C1q is a charge pattern 
recognition protein (460 kDa), consisting of 18 homologous polypeptide chains (6A, 6B and 
6C chains) with by a collagen like region (N terminal) with repeating Gly-X-Yaa triplets, and a 
globular head domain (C terminal), which bind to charge clusters or hydrophobic patches on 
targets. Each trimeric subunit has three globular head domains, called ghA, ghB, ghC. (b) SP-
D has an N-terminal triple-helical collagen region, followed by a trimerising α-helical coiled-
coil neck region, and C-terminal homotrimeric carbohydrate recognition domain (CRD). This 

























































primary subunit structure can associate further to yield a cruciform tetrameric 
supramolecule. 
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